Identifying locally actionable strategies to increase participant acceptability and feasibility to participate in Phase I cancer clinical trials

Author:

Staras Stephanie A. S.1ORCID,Wollney Easton N.1,Emerson Lisa E.2ORCID,Silver Natalie3,Dziegielewski Peter T.4,Hansen Marta D.1,Sanchez Gabriela1,D'Ingeo Dalila1,Johnson‐Mallard Versie5,Renne Rolf6,Fredenburg Kristianna7,Gutter Michael8,Zamojski Kendra8,Vandeweerd Carla1,Bylund Carma L.1

Affiliation:

1. Department of Health Outcomes and Biomedical Informatics University of Florida College of Medicine Gainesville Florida USA

2. Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences University of Florida Gainesville Florida USA

3. Department of Surgery Cleveland Clinic Cleveland Ohio USA

4. Department of Otolaryngology University of Florida College of Medicine Gainesville Florida USA

5. Center for Nursing Research College of Nursing, Kent State Kent Ohio USA

6. Department of Molecular Genetics and Microbiology University of Florida College of Medicine Gainesville Florida USA

7. Department of Pathology University of Florida College of Medicine Gainesville Florida USA

8. Department of Family, Youth and Community Sciences, Institute of Food and Agricultural Sciences University of Florida Gainesville Florida USA

Abstract

AbstractBackgroundRecruitment of cancer clinical trial (CCT) participants, especially participants representing the diversity of the US population, is necessary to create successful medications and a continual challenge. These challenges are amplified in Phase I cancer trials that focus on evaluating the safety of new treatments and are the gateway to treatment development. In preparation for recruitment to a Phase I recurrent head and neck cancer (HNC) trial, we assessed perceived barriers to participation or referral and suggestions for recruitment among people with HNC and community physicians (oncologist, otolaryngologist or surgeon).MethodsBetween December 2020 and February 2022, we conducted a qualitative needs assessment via semistructured interviews with a race and ethnicity‐stratified sample of people with HNC (n = 30: 12 non‐Hispanic White, 9 non‐Hispanic African American, 8 Hispanic and 1 non‐Hispanic Pacific Islander) and community physicians (n = 16) within the University of Florida Health Cancer Center catchment area. Interviews were analyzed using a qualitative content analysis approach to describe perspectives and identify relevant themes.ResultsPeople with HNC reported thematic barriers included: concerns about side effects, safety and efficacy; lack of knowledge and systemic and environmental obstacles. Physicians identified thematic barriers of limited physician knowledge; clinic and physician barriers and structural barriers. People with HNC and physicians recommended themes included: improved patient education, dissemination of trial information and interpersonal communication between community physicians and CCT staff.ConclusionsThe themes identified by people with HNC and community physicians are consistent with research efforts and recommendations on how to increase the participation of people from minoritized populations in CCTs. This community needs assessment provides direction on the selection of strategies to increase CCT participation and referral.Patient or Public ContributionThis study focused on people with HNC and community physicians' lived experience and their interpretations of how they would consider a future Phase I clinical trial. In addition to our qualitative data reflecting community voices, a community member reviewed the draft interview guide before data collection and both people with HNC and physicians aided interpretation of the findings.

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health

Reference35 articles.

1. American Cancer Society Cancer Action Network. Barriers to patient enrollment in therapeutic clinical trials for cancer—a landscape report. June 1 2023. Accessed June 1 2023.https://www.fightcancer.org/sites/default/files/National%20Documents/Clinical-Trials-Landscape-Report.pdf

2. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies

3. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

4. Adult Cancer Clinical Trials That Fail to Complete: An Epidemic?

5. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3